From Name

From Email

To Name

To Email

Message

Access uneven for 'most expensive cardiac medication in history'

from MedPage Today

Access uneven for 'most expensive cardiac medication in history' MedPage Today Not all amyloidosis patients at a major hospital system could get their hands on commercial tafamidis (Vyndaqel or Vyndamax), and when they did, it was often with financial assistance, researchers reported. From May to November 2019, immediately after FDA approval, 50 people were prescribed the transthyretin (TTR) protein stabilizer tafamidis, with 86% successfully obtaining the drug, according to a group led by Ahmad Masri, MD, MS, of Oregon Health and Science University in Portland. READ MORE

more